Which advantages over its rivals hold up, and why are they hard to copy?
Radspherin holds its edge through short-range alpha emission and receptor-independent action. Radium-224 alpha particles travel less than 0.1 mm, concentrating the dose within the cavity while sparing healthy tissue in this alpha-emitting therapy placed directly into a body cavity. Radspherin treats tumors regardless of antigen expression, widening the treatable patient group.
In-house production supports multi-center Phase 2 trials of Radspherin across Europe and North America. Oncoinvent operates an Oslo manufacturing site with radiopharmaceutical expertise. The FDA granted Fast Track Designation covering peritoneal metastases from ovarian cancer.
What could change its growth trajectory, and what would confirm it?
Faster ovarian-trial enrollment and broader site activity could advance Radspherin's clinical trajectory. On 18 June 2026, Oncoinvent announced that its ongoing ovarian Phase 2 trial had reached 50% recruitment, with 54 patients enrolled.
Ten hospitals across six countries are active in the ovarian trial. HIPEC is a single intraoperative procedure that delivers chemotherapy directly into the abdominal cavity.
Which risks could break the thesis, and what would warn of them?
The ovarian trial's incomplete enrollment could impair the interim-data catalyst on which Radspherin's near-term thesis rests, since the ongoing Phase 2 trial in ovarian peritoneal metastases has reached the 50% recruitment milestone and interim data is expected in 2026. Radspherin, Oncoinvent's lead candidate, is an alpha radiation therapy for cancers that have spread to body cavities.
Thor Medical will provide thorium-228 as the starting material for radium-224, sourced from the AlphaOne plant now under construction. The FDA has granted Fast Track Designation for the ovarian indication. Oncoinvent's in-house manufacturing and supply chain can supply Radspherin for multi-center Phase 2 studies.
What does the product do for its buyer, and how is it delivered?
Radspherin is a candidate for treating cancers locally when they have spread to body cavities, using instilled radium-224 microparticles to create a localized radiation field. It consists of calcium carbonate microparticles containing radium-224, and after instillation the particles spread across the targeted body cavity.
Radium-224 alpha radiation reaches less than 0.1 mm. The range concentrates treatment inside the body cavity and minimizes exposure to surrounding healthy tissues.